BPC August 12 update

​Regeneron REGN promises with ebola treatment; Portola PTLA offering

Price and Volume Movers

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that its trial of REGN-EB3 evaluating therapies for Ebola virus infection was stopped early because of superiority to ZMapp.

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) announced it intends to offer $200m of its common stock in an underwritten public offering. Shares are trading down 5% to $29.15 after hours.

Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) shares closed up 20% to $1.00 after trading up as high as $1.56 earlier in the session. No news was announced by the company. Sienna mentioned last week that it would be exploring financial and strategic alternatives.

Eidos Therapeutics, Inc. (Nasdaq:EIDX) announced that BridgeBio Pharma, Inc. will purchase all of the remaining common stock of the company not already owned by BridgeBio, which current owns approximately 66.6%. BridgeBio would acquire shares for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos stock. Shares of Eidos closed up 6% to $37.32.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Miragen Therapeutics, Inc. (MGEN): $1.23; +16%.

Pfenex Inc. (PFNX): $7.21; +14%.

AMAG Pharmaceuticals, Inc. (AMAG): $11.83; +14%.

AxoGen, Inc. (AXGN): $14.61; +9%.

Opiant Pharmaceuticals, Inc. (OPNT): $15.16; +8%.


Progenics Pharmaceuticals, Inc. (PGNX): $3.90; -16%.

Deciphera Pharmaceuticals, Inc. (DCPH): $19.95; -15%.

Autolus Therapeutics plc (AUTL): $9.79; -14%.

Adaptimmune Therapeutics plc (ADAP): $1.71; -12%.

Rhythm Pharmaceuticals, Inc. (RYTM): $18.81; -12%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

CYCN – Cyclerion Therapeutics Inc.
IW-1973 (Praliciguat)
Diabetic nephropathy

Phase 2 Phase 2 trial did not meet primary endpoint - October 30, 2019.
$51.9 million

IMUX – Immunic Inc.
Primary Sclerosing Cholangitis

Phase 2 Phase 2 commencement of enrolment announced August 12, 2019.
$71.6 million

KNSA – Kiniksa Pharmaceuticals Ltd.
Rilonacept (RHAPSODY)

Phase 3 Phase 3 data due 2H 2020.
$582.3 million

KNSA – Kiniksa Pharmaceuticals Ltd.
Atopic dermatitis

Phase 1b Phase 1b data showed no meaningful benefit - August 12, 2019.
$582.3 million

KTOV – Kitov Pharma Ltd.
Squamous cell carcinoma of the head & neck (SCCHN)

Phase 1 Phase 1/2 trial to be initiated 1Q 2020.
$14.1 million

MLND – Millendo Therapeutics Inc.
Prader-Willi syndrome (PWS)

Phase 2/3 Phase 2b data due 1H 2020. Completion of enrolment announced November 13, 2019.
$83.7 million

MNK – Mallinckrodt plc
Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)

Phase 1/2 Phase 2 commencement of dosing announced August 12, 2019. To be completed 2Q 2020.
$286.8 million

MTEM – Molecular Templates Inc.
MT-3724 and chemotherapy
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Phase 2 Phase 2 update due 4Q 2019.
$452.5 million

MTEM – Molecular Templates Inc.
MT-3724 and Revlimid
Diffuse large B-cell lymphoma (DLBCL)

Phase 2 Phase 2 update due 4Q 2019.
$452.5 million

SRNE – Sorrento Therapeutics Inc.
Lumbosacral radicular pain (sciatica)

Phase 2/3 Phase 3 top-line data due 1H 2020.
$579.2 million

TNXP – Tonix Pharmaceuticals Holding Corp.
Post-traumatic stress disorder (PTSD)

Phase 3 Phase 3 interim analysis 1Q 2020 with top-line data due 2Q 2020.
$2.3 million

TYME – Tyme Technologies Inc.
Prostate cancer

Phase 2 Pivotal stage initiation announced September 25, 2019.
$122 million

TYME – Tyme Technologies Inc.
Pancreatic cancer

Phase 2 Phase 2 presentation at ESMO September 29, 2019.
$122 million